BRIEF-Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

Reuters
19 May
BRIEF-Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder

May 19 (Reuters) - Altimmune Inc ALT.O:

  • ALTIMMUNE ANNOUNCES INITIATION OF RECLAIM PHASE 2 TRIAL EVALUATING THE EFFICACY AND SAFETY OF PEMVIDUTIDE IN ALCOHOL USE DISORDER (AUD)

  • ALTIMMUNE INC - IMPACT PHASE 2B TRIAL TOPLINE DATA EXPECTED IN Q2 2025

  • ALTIMMUNE INC - PHASE 2 TRIAL IN ALD TO INITIATE ENROLLMENT IN Q3 2025

Source text: ID:nGNXYx2DK

Further company coverage: ALT.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10